Esperion Logo (primary).png
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2017 16:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 18, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Logo (primary).png
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 12, 2017 16:30 ET | Esperion Therapeutics, Inc.
Fireside Chat on Wednesday, May 17, 2017 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time ANN ARBOR, Mich., May 12, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion Logo (primary).png
Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
March 28, 2017 16:30 ET | Esperion Therapeutics, Inc.
Fireside Chat on Tuesday, April 4, 2017 at 1:40 p.m. Eastern Time ANN ARBOR, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company...
Esperion Logo (primary).png
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
March 20, 2017 07:30 ET | Esperion Therapeutics, Inc.
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...
Esperion Logo (primary).png
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
March 07, 2017 08:30 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...
Esperion Logo (primary).png
Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session
March 06, 2017 08:30 ET | Esperion Therapeutics, Inc.
Company to Host Webcast on Sunday, March 19, 2017 at 5:30 p.m. Eastern Time ANN ARBOR, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management...
Esperion Logo (primary).png
Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
January 25, 2017 08:05 ET | Esperion Therapeutics, Inc.
Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD...
Esperion Logo (primary).png
Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
January 09, 2017 08:05 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...
Esperion Logo (primary).png
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
January 08, 2017 16:00 ET | Esperion Therapeutics, Inc.
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...
Esperion Logo (primary).png
Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017 17:00 ET | Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...